Abstract. Hepatocyte cell adhesion molecule (hepaCAM), a tumor-suppressor gene, is rarely expressed in bladder carcinoma. However, little is known concerning the mechanisms of low hepaCAM expression in bladder cancer. Abnormal hypermethylation in the promoter plays a crucial role in cancer by silencing tumor-suppressor genes, which is catalyzed by DNA methyltransferases (DNMTs). In the present study, a total of 31 bladder cancer and 22 adjacent tissues were assessed by immunohistochemistry to detect DNMT3A/3B and hepaCAM expression. Methylation of hepaCAM was determined by methylation-specific polymerase chain reaction (MSP). The mRNA and protein levels of DNMT3A/3B and hepaCAM were determined by RT-PCR and western blot analysis after treatment with 5-azacytidine (AZAC). Following AZAC treatment, the proliferation of bladder cancer cells was detected by CCK-8 and colony formation assays. Cell cycle distribution was examined by flow cytometry. To further evaluate the tumor-suppressive roles of AZAC and the involved mechanisms, the anti-tumorigenicity of AZAC was tested in vivo. The expression of DNMT3A/3B protein was markedly increased in the bladder carcinoma tissues (P<0.05), and had a negative linear correlation with hepaCAM expression in the same patients according to P<0.05). The MSP results indicated that the hepaCAM gene was hypermethylated in three bladder cancer cell lines. Furthermore, we found that downregulation of DNMT3A/3B expression, after treatment with AZAC, reversed the hypermethylation and expression of hepaCAM in bladder cancer cells. In addition, AZAC inhibited the proliferation of bladder cancer cells and arrested cells at the G0/G1 phase. The in vivo results showed that expression of DNMT3A/3B and hepaCAM as well as tumor growth of nude mice were markedly altered which corresponded with the in vitro results. Due to the ability to reactivate expression of hepaCAM and inhibit growth of bladder cancer cells, AZAC may represent an effective treatment for bladder cancer.
Introduction
Hepatocyte cell adhesion molecule (hepaCAM), also known as GliaCAM, is located on chromosome 11q24 and encodes a putative Ig-like cell adhesion molecule with 416 amino acids. It is a newly identified cell adhesion molecule which belongs to the immunoglobulin superfamily (1, 2) . It was discovered in normal liver tissues, but is decreased during the development of human hepatocellular carcinoma (3) . The loss of hepaCAM in cancer could help to promote tumorigenesis. Overexpression of hepaCAM in cancer cells was found to inhibit cell growth and induce cellular senescence and differentiation (4, 5) . Our previous studies showed that exogenous hepaCAM inhibits renal cell growth by arresting cells at the G0/G1 phase and promotes c-myc degradation (6, 7) . We also discovered that overexpression of hepaCAM inhibited the cell proliferation of human bladder carcinoma (8) . These findings suggest that hepaCAM acts as a tumor-suppressor gene. Nevertheless, little is known about the mechanisms of low hepaCAM expression in bladder cancer.
Abnormal hypermethylation in the promoter plays a crucial role in cancer by silencing tumor-suppressor genes. Particularly, downregulation of many tumor-suppressor genes and DNA repair genes, such as p16, p15, Rb, VHL, E-cadherin, GSTP1, MGMT and hMLH1, is associated with aberrant methylation in cancer cell lines and primary tumors (9) . In mammalians, DNA methylation refers to the addition of a methyl group to the cytosine ring of those cytosines that precede a guanosine (referred to as CpG dinucleotides) to form 5-methylcytosine (10) , which is catalyzed by three different enzymes, DNMT1, DMNT3A and DNMT3B. DNMT3A and DNMT3B are most likely responsible for de novo cytosine methylation at previously unmethylated CpG sites, whereas the maintenance methyltransferase DNMT1 copies pre-existing (11, 12) . Abundant evidence shows that DNA methyltransferases (DNMTs) are overexpressed in various types of cancers (13) (14) (15) . DNMTs have become valuable therapeutical targets of cancers by the use of DNMT inhibitors (DNMTi) (16) . 5-Azacytidine (AZAC) and 5-aza-2-deoxycytidine (decitabine), characterized as DNMT inhibitors, were initially used as antimetabolites and cytotoxic agents in phase I/II studies of malignancies (17, 18) . Meanwhile, aberrant hypermethylation of DNA can be reverted by DNMTi. We hypothesized that overexpression of DNMT3A/3B may also contribute to hepaCAM silencing in bladder cancer.
5-Azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene
In the present study, we detected the expression of DNMT3A/3B and hepaCAM in bladder cancer tissues. There was a negative linear correlation between DNMT3A/3B and hepaCAM expression in the same bladder carcinoma patients. High expression of DNMT3A/3B and aberrant hypermethylation in promoter CpG islands of the hepaCAM gene were found in bladder cancer cell lines. Furthermore, we found that downregulation of DNMT3A/3B expression, after treatment with AZAC, reversed the hypermethylation and expression of hepaCAM. Furthermore, AZAC inhibited the growth of bladder cancer in vitro and in vivo, providing a new insight into the therapeutic strategy of bladder cancer.
Materials and methods
Tissue specimens. Thirty-one urothelial carcinoma samples and 22 corresponding adjacent tissues were collected from patients who underwent total cystectomy. Nine patients were treated with transurethral resection of bladder carcinoma but no adjacent tissue was obtained. Patients were enrolled at the Department of Urology at the First Affiliated Hospital of Chongqing Medical university. All tissue specimens were confirmed to be bladder cancer or normal histologically, and histological grade and stage were determined according to uICC guidelines. Written informed consent was received from all participants. This study was approved by the Ethics Committee of Chongqing Medical university. All tissue specimens were stored at -80˚C before the experiment.
Immunohistochemistry. The assay was performed as described previously (19) . In brief, paraffin wax-embedded tissue sections were dewaxed, rehydrated and microwaved for 30 min in sodium citrate buffer to retrieve antigen epitopes. Endogenous peroxidase activity was suppressed by 3% H 2 O 2 and blocked by goat serum 5% BSA. Diluted primary polyclonal rabbit antibodies against hepaCAM (ProteinTech, China), DNMT3A and DNMT3B (Immunoway Biotechnology, China) were added and left at 4˚C overnight. As secondary reagents, we used biotin-labeled anti-IgG and avidin-biotin horseradish peroxidase complex, followed by staining with the chromogen diaminobenzidine (Zhongshan, China) until a brown color developed. Slides were counterstained with Mayer's hematoxylin and differentiated in a solution containing 1% hydrochloric acid and 99% ethanol. Cell nuclei were stained blue using lithium carbonate. Sections were dehydrated and a transparent coverslip was added to enable observation by microscopy.
Cells and culture. Human bladder cancer cell lines (T24, EJ and BIu-87) were obtained from the American Type Culture Collection (ATCC; uSA). All the cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (both from Gibco, uSA) under standard culture conditions (5% CO 2 at 37˚C).
MTT assay. To determine the optimal drug doses, bladder cancer cells (T24, EJ and BIu-87) were seeded in 96-well plates at a density of 1x10 4 cells/well for 12 h and treated with 5-azacytidine (Sigma, uSA) at different concentrations (0.5, 1, 2, 3, 4, 5, 6 and 7 µg/ml). Three plates were seeded, and the cells were cultured for 24, 48, 72 and 96 h, respectively. Before removal from the incubator, the cells were incubated with 20 µl 0.5 mg/ml MTT (Sigma) for an additional 4 h. Culture medium was discarded, and 150 µl dimethylsulfoxide (DMSO; Sigma) was added to dissolve the formazan crystals. The absorbance was measured in a microplate reader at an optical density (OD) of 492 nm. Inhibition rate was calculated using the formula: IR = (1 -experiment group/control group) x 100%.
CCK-8 assay.
To evaluate the cell viability, the CCK-8 Kit (Beyotime, China) was applied according to the manufacturer's instructions. The results were repeated in triplicate. The OD of the untreated controls was measured as 100% survival.
Colony formation assay. Bladder cancer cells were seeded into 6-well plates at a density of 300 cells/well. After a 48-h incubation, cells were treated with AZAC or DMSO. After 13 days, the cells were fixed with methanol for 20 min and stained with crystal violet. Colonies were observed and images were captured under a microscope.
Flow cytometric assay. Bladder cancer cells (1x10 6 ) treated with AZAC or DMSO were cultured in 6-well plates for 48 h. The cells were collected in cold phosphate-buffered solution (PBS), fixed in 70% ethanol, and stored at 4˚C for subsequent cell cycle analysis. Procedures for testing the cell cycle have been previously described (7).
Methylation-specific polymerase chain reaction assay.
Genomic DNA was extracted from bladder cancer cells according to the instructions provided in the TIANamp Genomic DNA kit (Tiangen Biotech, China). The bisulfite modification procedures were carried out using EZ DNA Methylation-Gold™ kit (Zymo Research, uSA). Methylationspecific polymerase chain reaction (MSP) was performed to detect the methylation status of the hepaCAM gene (M, methylation status; u, unmethylation status). The PCR conditions were as follows: pre-denaturation at 98˚C for 10 min, denaturation at 95˚C for 10 sec; annealing at 58.4˚C (U)/61.8˚C (M) for 60 sec; extension at 72˚C for 30 sec, final extension at 72˚C for 5 min. Primer sequences were: hepaCAM(M) forward, AGAA TTCGGTTTCGGAGTTTC and reverse, CTAAACGACGAC GAATATATCCG; and hepaCAM(u) forward, AGAATTTGG TTTTGGAGTTTTGA and reverse, CCTAAACAACAACAA ATATATCCAAC. PCR products were separated on 3% agarose gel.
Reverse transcription and RT-PCR.
Total RNA was isolated from bladder cancer cells using RNAiso Plus (Takara, Japan) according to the manufacturer's instructions. Complementary DNA was synthesized using a reverse transcription kit (Takara) according to the manufacturer's protocol. The PCR conditions consisted of predenaturing at 95˚C for 5 min, denaturing at 95˚C for 10 sec, annealing for 50 sec, extension at 72˚C for 1 min, a total of 35 cycles from denaturing, and a final extension at 72˚C for 5 min. Primer sequences were as follows: hepaCAM forward, TACTGTAGATGTGCCCATTTCG and reverse, CTTCTGGTTTCAGGCGGTC; DNMT3A forward, GGCGTTAGTGACAAGAGGG and reverse, TGGACTGGG AAACCAAATA; DNMT3B forward, CAAAGAGTTGGGC ATAAAGG and reverse, GCGTGAGTAATTCAGCAGGT; and β-actin forward, CACCACACCTTCTACAATGAGC and reverse, GTGATCTCCTTCTGCATCCTGT. The β-actin gene was used as an internal standard. All RT-PCR reactions were executed in triplicate. Each PCR product was electrophoretically tested on 1.5% agarose gel.
Protein extraction and western blot analysis. Total protein extraction from cells and tissues was performed using RIPA buffer supplemented with protease inhibitor (PMSF) and phosphatase inhibitors (NaF and Na 3 VO 4 ) (Roche, Switzerland). The BCA Protein Assay kit (Beyotime) was used to detect the quantity of each sample according to the manufacturer's instructions. Proteins (100 µg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Invitrogen, uSA). Then the proteins were electrotransferred onto polyvinylidene difluoride membranes (Millipore, uSA). The membranes were blocked with 5% skim milk at room temperature for 1 h and then incubated with the primary antibody against hepaCAM, DNMT3A, DNMT3B and β-actin (Zhongshan, China) overnight at 4˚C. Membranes were washed twice with TBST and once with TBS, and then incubated with the HRP-conjugated secondary antibody for 1 h at room temperature. Proteins were visualized using a chemiluminescence (ECL) reagent (Millipore, Billerica, MA, uSA), and the densities of the bands were quantified and normalized to that of β-actin by Quantity One software. The experiments were performed as described previously (20) .
Tumor model. Nude mice (4-6 weeks of age) were purchased from the Animal Institute of the Chinese Medical Academy (Beijing, China). Viable EJ cells (3x10 6 ) resuspended in PBS were injected into the right flanks of 8 male nude mice. The mice were randomized into two groups: group A (DMSO group) and group B (AZAC group) after 2 weeks. Subsequently, AZAC was injected into mice in group B and DMSO in group A every three days for 6 times. The weight of each nude mice was determined daily for 3 weeks. After 3 weeks, all mice were sacrificed. The xenograft tumor weight was measured at the terminal time, and tumor tissues were resected for hematoxylin and eosin (H&E) staining and immunohistochemical examination of hepaCAM, DNMT3A and DNMT3B. All animal experiments were approved by the Institutional Animal Care and use Committee (IACuC) of Chongqing Medical university.
Statistical analysis. All statistical analyses were performed with SPSS 19.0 software using paired-samples t-test. Data are shown as mean ± SD, and P<0.05 served as the criterion for statistical significance. 
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Results
High expression of DNMT3A/3B and low expression of hepaCAM are noted in the bladder cancer tissues. To investigate whether there was any correlation between DNMT3A/3B and hepaCAM expression, we used anti-DNMT3A/3B and anti-hepaCAM antibodies to detect the expression of DNMT3A/3B and hepaCAM in the bladder cancer and adjacent tissues. The results showed that DNMT3A/3B was strongly expressed in the bladder cancer tissues, but weakly expressed in the adjacent tissues. However, in regards to hepaCAM, the expression levels in the adjacent tissues were higher than levels in the cancer tissues ( Fig. 1A and B) . We made use of the mean density for estimating the protein expression levels of DNMT3A/3B and hepaCAM. The results revealed a negative linear correlation between DNMT3A/3B and hepaCAM expression in the same patients according to Pearson's analysis (r=-0.7176/-0.7127, P<0.05, Fig. 1C ). However, there was no significant difference in expression levels in regards to age, gender, and disease recurrence (Tables I and II) . In contrast, protein lysates were extracted from 10 bladder cancer patient samples. Importantly, western blotting with antibodies against DNMT3A/3B showed that 9 of the 10 bladder cancer tissues had elevated levels of DNMT3A/3B, respectively, whereas only 1 of the 10 adjacent normal tissues had detectable expression of DNMT3A/3B (P<0.05, Fig. 1D and E) .
Optimal concentration and treatment time for AZAC.
To confirm the mode of action of AZAC in bladder cancer cells, we determined the absorption at a variety of concentrations and times. We calculated the IR with the above-documented equation. The results indicated that bladder cancer cell proliferation was markedly inhibited by AZAC in a concentration-and dosedependent manner (P<0.05, Table III ). According to Table III, 4 µg/ml (BIU-87) and 5 µg/ml (T24 and EJ) was confirmed as the most appropriate concentrations. The dose-effect curve indicated that the bladder cancer cell IR gradually increased with prolongation of treatment time at the same concentration compared with the controls (P<0.05, Fig. 2A ). Based on these results, concentrations of 4 µg/ml (BIu-87 cells) and 5 µg/ml (T24 and EJ cells) AZAC were selected as the optimal treatment conditions for the following experiments.
AZAC reverses the hypermethylation of hepaCAM. Hypermethylation of the hepaCAM promoter was apparently observed in the T24, EJ and BIu-87 cell lines by use of MSP. In addition, the hepaCAM promoter was obviously demethylated by 5 µg/ml of AZAC in the T24 and EJ cell lines, and 4 µg/ml of AZAC in the BIu-87 cell line at 48 h (Fig. 2B) .
Suppression of DNMT3A/3B induces re-expression of hepaCAM.
Based on our findings, we analyzed the mRNA and protein expression of DNMT3A/3B and hepaCAM by RT-PCR and immunoblotting. The results revealed that DNMT Table II . Comparison of the protein expression of DNMT3B and hepaCAM in the bladder cancer cases according to clinicopathological parameters. inhibitor AZAC inhibited both the mRNA and protein levels of DNMT3A/3B in the bladder cancer cell lines. AZAC not only reversed the expression of hepaCAM mRNA ( Fig. 2C and D) but also its protein level ( Fig. 2E and F) . These results suggest that the inactivation of DNMT3A/3B by AZAC treatment may participate in restoring the expression of the tumor-suppressor gene hepaCAM.
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AZAC inhibits cell proliferation.
To investigate the effect of AZAC against bladder cancer cells, cell proliferation was detected by CCK-8 assay, colony formation assay and flow cytometry. The results showed that the growth of bladder cancer cells was inhibited after exposure to AZAC for 48 h compared with the control groups (P<0.05, Fig. 3A ). This result was further supported by a colony formation assay. As shown in Fig. 3B and C, there was a significantly lower colony formation potential in the AZAC-treated cells compared to that in the DMSO treatment groups (P<0.05). It has been reported that the growth inhibition of AZAC is always associated with cell cycle arrest (21) . To evaluate the exact cell cycle phase, bladder cancer cells were inspected at 48 h, under stimulation by 4 µg/ml (BIu-87) and 5 µg/ml (T24 and EJ) AZAC. The results revealed that bladder cancer cells treated with AZAC had a significant accumulation in the G0/G1 phase compared to the controls (P<0.05, Fig. 3D and E). These data indicate that the growth of bladder cancer cells was markedly inhibited by AZAC.
Effects of AZAC on nude mice.
To further investigate the tumorsuppressive function of AZAC and its mechanisms in vivo, the antitumorigenicity of AZAC was tested in nude mice. Thirty days after injection, tumors were excised from the tested mice for further analysis. The volume and weight of the tumors in the AZAC treatment groups were significantly decreased, compared with the control groups (P<0.05, Fig. 4A-D) .
Immunohistochemistry was further performed to analyze the expression of DNMT3A/3B and hepaCAM in the xenograft tumors. Numerous tumor cells with high nuclear fragmentation were found in H&E-stained sections from the DMSO treatment groups compared with the AZAC groups. Furthermore, low expression of DNMT3A/3B but high levels of hepaCAM immunostaining were observed in the AZAC treatmentderived tumor tissues (Fig. 4E) . Taken together, these data indicate that AZAC acts as an antitumor agent, suppressing the proliferation of bladder cancer and enhancing the expression of hepaCAM via downregulation of the levels of DNMT3A/3B.
Discussion
Bladder cancer ranks fourth in regards to the worldwide cancer incidence and is the seventh leading cause of mortality from cancer (22) . The main features of bladder cancer are disease recurrence and progression (23) . Research has confirmed that bladder cancer results from interactions among exogenous, genetic and epigenetic factors. Previous studies have demonstrated that the most common risk factors of bladder cancer are smoking and occupational exposure (23) (24) (25) . However, more and more studies have aimed to investigate the molecular mechenisms of bladder carcinogenesis in recent years. Various studies have discovered that inactivation of one or more tumorsuppressor genes, such as p16INK4a, FHIT, LAMC2, APC, hMLH1 and E-cadherin, may be an early event in the tumorigenic pathway leading to bladder cancer (26) (27) (28) (29) .
HepaCAM localized on the cell surface has a role in cell-cell adhesion, and acts as a tumor suppressor. We have been researching the reason for the absence of hepaCAM in bladder cancer. In a previous study, we found that exon 2 methylation of hepaCAM may be one of the reasons for its low expression in bladder cancer tissues and cell lines (30) . However, the precise mechanism of low hepaCAM expression in bladder cancer still needs to be elucidated.
In cancer, hypermethylation of CpG islands, regarded as regions of DNA 0.5-4 kb with C+G content >0.5 (31) (32) (33) , contributes to transcription silencing of tumor-suppressor genes. There is mounting evidence that abnormal hypermethylation of the promoter is the mechanism involved in the silencing of tumor-suppressor genes in tumorigenesis. For example, RASSF1A is methylated in lung and breast cancers, and hypermethylation of the CDH1 promoter is noted in gastric cancer (34) . In the past few years, more and more candidate tumor-suppressor genes have been found to be silenced by promoter hypemethylation in cancers. In the present study, we predicted a CpG island in the hepaCAM promoter by an online database (http://rulai.cshl.org/tools/FirstEF/) and designed meth-primers (http://www.urogene.org/methprimer/index1. html) to detect the methylation status of the CpG island in the hepaCAM promoter. Our results demonstrated that aberrant hypermethylation occurred in the CpG island of the hepaCAM gene promoter, which contributed to the absence of hepaCAM in the bladder cancer cells (T24, EJ and BIu-87). Methylation was catalyzed by DNMTs. Many previous studies have shown that DNMT3A/3B are overexpressed in cancers. For example, the level of DNMT3A/3B was signifi- Table III . Inhibition rates for different concentrations of AZAC in the bladder cancer cells. .05, compared with the DMSO group. (E) Western blot analysis showed that hepaCAM was re-activated but DNMT3A and DNMT3B were downregulated in three bladder cancer cell lines after AZAC treatment compared with the DMSO group. β-actin was used as control. (F) Intensities were quantitated by Quantity One software; cantly higher in gastric cancer than in normal tissues (35) , and its expression in prostate carcinoma tissues was higher than that in adjacent normal tissues (36) . In the present study, we detected the expression of DNMT3A/3B and hepaCAM in bladder cancer. Correlations between DNMT3A/3B and hepaCAM in bladder cancer patients suggested that a low level of hepaCAM was closely related with high expression of DNMT3A/3B in bladder carcinomas. Then, we found that AZAC reversed the high methylation of hepaCAM and restored its level via downregulation of the expression of DNMT3A/3B, at not only the mRNA but also the protein level, in the bladder cancer cell lines. Previous studies also showed similar findings in prostate cancer cells under mahanine treatment (37) . These studies indicate that the precise mechanism of low hepaCAM expression in bladder cancer may be abnormal hypermethylation of hepaCAM induced by high levels of DNMT3A/3B.
In the clinic, AZAC has been used as a drug for hematopoietic disorders and as an anticancer treatment strategy for solid tumors. Fenaux et al showed that AZAC significantly extended the overall survival of patients with myelodysplastic syndrome (MDS, a bone marrow stem cell disorder). Likewise, AZAC was found to suppress the cell growth of three different neuroendocrine tumors in vitro (38) . In the present study, CCK-8 and colony-formation assays revealed that AZAC inhibited the proliferation of bladder cancer cells. For the first time, we also provided evidence for the accumulation of G0/G1 cell cycle markers following AZAC treatment, suggesting that AZAC inhibited cell proliferation by inducing G0/G1 cell growth arrest. These data were in concordance with a previously published report that adenovirus-hepaCAM treatments induce G0/G1 growth arrest in bladder cancer (19) . Thus, our data suggest that AZAC may represent an effective therapeutic intervention for bladder cancer.
To address the regulation mechanism and apparently central role of AZAC in vitro, we performed in vivo experiments to validate these results. First, in vivo tests revealed that AZAC inhibited tumor growth, which was in line with a previous study (39) . Next, immunohistochemistry showed low protein levels of DNMT3A/3B and high protein expression of hepaCAM in the AZAC-treated tumors, which were in accordance with our in vitro tests. However, the sites of methylation of hepaCAM in bladder cancer cells need to be further explored.
In summary, our study showed that DNMT3A/3B expression was increased while hepaCAM protein expression was decreased in bladder cancer tissues, and there was a negative linear correlation between them. HepaCAM was silenced by its promoter hypermethylation and was re-activated by methylation inhibitor AZAC via downregulation of the expression of DNMT3A/3B. Furthermore, AZAC inhibits the growth of bladder cancer in vitro and in vivo, providing a new insight into the therapeutic strategy of bladder cancer.
